Market News AIOpen the app

Jasper Therapeutics shared its Q3 2026 results and news about its kidney study and buying Kira Pharmaceuticals.

ResultsRead the original at SEC EDGAR
Good for JSPR

Jasper completed enrollment in its first kidney-disease study group and started work in other groups. This advances its drug studies, though no patient results are reported yet.

JSPR · Jasper Therapeutics, Inc.

AI read · Good for JSPR

The AI's read

More patients are now being studied across several kidney diseases. Early findings could help show whether the treatment helps. The update does not report patient results yet. Jasper also says its Kira purchase came with about $132 million from a preferred-stock sale. That provides cash for its work, but the report does not say how long the cash will last.

Get alerts for JSPR

Follow Jasper Therapeutics, Inc. (JSPR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for JSPR
Free on the App Store and Google Play, or on the web.